Canertinib (CI-1033)

CAS : 267243-28-7

Ref. 3D-SKA24328

Informations sur le produit

• Nom: Canertinib (CI-1033)
• Synonymes: 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline, Canertinib base, Cl 1033, N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide, N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide, N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[2-(morpholin-4-yl)ethoxy]quinazolin-6-yl}prop-2-enamide, N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide
• CAS: 267243-28-7

Description

Canertinib is a small molecule that inhibits the protein synthesis of cancer cells by inhibiting the epidermal growth factor receptor (EGFR). It has been shown to have therapeutic effects against lung, brain, and breast cancers. Canertinib also binds to the EGFR monoclonal antibodies, which are used in cancer immunotherapy. This drug has been shown to inhibit the growth of human osteosarcoma cells in vitro and in vivo. Canertinib has also been shown to inhibit fatty acid synthesis and cell signaling pathways that regulate cancer cell growth.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 485.94 g/mol
• Formule: C₂₄H₂₅ClFN₅O₃
• Degré de pureté: Min. 95%